Zhitong Financial App News, Federal Pharmaceutical (03933.HK) announced that the Toku insulin liraglutide injection (iDeglira) independently developed by Zhuhai Federal Biomedical Co., Ltd., a wholly-owned subsidiary of the company, has been accepted for marketing registration by the China National Drug Administration. The acceptance number is CXSS2600154. The company is the first company in China to submit an application for marketing registration of German insulin liraglutide biosimilar drugs.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Federal Pharmaceutical (03933.HK) announced that the Toku insulin liraglutide injection (iDeglira) independently developed by Zhuhai Federal Biomedical Co., Ltd., a wholly-owned subsidiary of the company, has been accepted for marketing registration by the China National Drug Administration. The acceptance number is CXSS2600154. The company is the first company in China to submit an application for marketing registration of German insulin liraglutide biosimilar drugs.